CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: CH6001
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 44
- Registration Number
- NCT05431426
- Locations
- 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 44
- Registration Number
- NCT05373953
- Locations
- 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Beclomethasone Dipropionate/Formoterol Fumarate
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1377
- Registration Number
- NCT05292586
- Locations
- 🇺🇸
Chiesi Clinical Trial Site 840833, Houston, Texas, United States
🇺🇸Chiesi Clinical Trial Site 840819, Miami, Florida, United States
🇺🇸Chiesi Clinical Trial Site 840887, Miami, Florida, United States
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion
Completed
- Conditions
- Fabry Disease
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 23
- Registration Number
- NCT05186324
- Locations
- 🇺🇸
#06, Dallas, Texas, United States
🇧🇪#22, Antwerp, Belgium
🇺🇸#03, Atlanta, Georgia, United States
CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 106
- Registration Number
- NCT05097014
- Locations
- 🇩🇪
PAREXEL International GmbH Early Phase Clinical Unit Berlin, Berlin-Spandau, Berlin Spandauer Damm, Germany
Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA
Phase 4
Terminated
- Conditions
- Asthma
- Interventions
- Drug: Administration via pressurized metered dose inhaler (pMDI)
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 320
- Registration Number
- NCT05018598
- Locations
- 🇭🇺
Simplex Kft, Nyíregyháza, Hungary
Expanded Access to Velmanase Alfa
- Conditions
- Alpha-Mannosidosis
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Registration Number
- NCT04959240
Study in Adult Patients With Moderate to Severe Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Behavioral: Exploratory study on patient's perception of Asthma symptoms
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 78
- Registration Number
- NCT04886999
- Locations
- 🇮🇹
Chiesi 38011, Bari, Italy
🇮🇹Chiesi 38009, Battipaglia, Italy
🇮🇹Chiesi 38006, Cagliari, Italy
Functional Respiratory Imaging Study
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 25
- Registration Number
- NCT04876677
- Locations
- 🇧🇪
AZ Zeno Knokke-Heist, Knokke, Belgium
🇧🇪AZ Delta, Roeselare, Belgium
🇭🇺CRU Hungary Ltd, Miskolc, Hungary
Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)COPD
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 8
- Registration Number
- NCT04756960
- Locations
- 🇬🇧
Covance - Clinical Research Unit, Leeds, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath